<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60038">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324374</url>
  </required_header>
  <id_info>
    <org_study_id>813061</org_study_id>
    <nct_id>NCT02324374</nct_id>
  </id_info>
  <brief_title>Endocytoscopy and Colorectal Neoplasia</brief_title>
  <official_title>The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      This will be a pilot study to evaluate the role of endocytoscopy in classifying colorectal
      polyps in vivo. The primary outcomes will be to determine the key endocytoscopy image
      features of neoplastic and non-neoplastic colorectal polyps. The target population will
      include adult subjects undergoing screening and surveillance colonoscopies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer has been recognized as the second most common cause of cancer related
      death in the US (1). Most colorectal cancers arise from adenomatous polyps that progress.
      Colon polyps are usually classified as neoplastic (adenoma and carcinoma) and non-neoplastic
      (most commonly hyperplastic). Standard endoscopic inspection cannot reliably distinguish
      between polyps types. Thus, all visualized polyps during standard colonoscopies are
      typically removed. Since almost half of all polyps are hyperplastic, a large proportion of
      unnecessary polypectomies increase the time, risk, and cost of colonoscopies.

      Various studies have showed improved diagnostic accuracy of different types of polyps when
      broad field techniques such as chromoendoscopy with the use of topical stains were used to
      detect and characterize lesions (2-4). Chromoendoscopy, though an approved method of lesion
      characterization during endoscopic evaluation of colorectal lesions, is time consuming and
      non-standardized. Recently small field techniques such as confocal microscopy and
      endocytoscopy have been introduced enabling visualization of the gastrointestinal tract at a
      cellular level, thus allowing diagnosis and classification of colorectal lesions in vivo.

      Confocal endomicroscopy used along with chromoendoscopy to detect and characterize lesions
      has been studied extensively and reported to have a high accuracy in diagnosing neoplastic
      and nonneoplastic lesions of the gastrointestinal tract (5-12). One of the major limitations
      of the confocal system is the mandatory use of dyes such as topical Acriflavine or
      intravenous Fluorescein. However, there are issues with the application of these dyes; the
      risk of DNA damage with Acriflavine reduced its use. In addition, although intravenous
      fluorescein is FDA approved for diagnostic fluorescein angiography, its gastrointestinal
      application is an off-label indication and considered class IIb by the FDA. The other major
      limitation of the current confocal system is that it requires a dedicated confocal endoscope
      marketed by a single manufacturer. Thus, the use of confocal imaging requires purchase of
      specific confocal endoscopes.

      Endocytoscopy is based on the technology of light-contact microscopy. The current
      endocytoscopy system (ECS) consists of two prototypes; Prototype one gives a low
      magnification (XEC300) with a maximal 450X magnification and field of view of 300X300 um,
      Prototype two provide a high magnification (XEC120) with a maximal 1100X magnification and a
      field of view of 120X120 um. In contrast to confocal endomicroscopy, the endocytoscopes can
      be easily passed through an accessory channel of the conventional therapeutic endoscope.
      This method does not require the use of intravenous contrast agents. Instead, it uses
      topical staining such as methylene blue or crestyl violet, which is applied routinely to
      facilitate visualization and removal of advanced colorectal polyps through endoscopic
      mucosal resection during colonoscopy.

      The endocytoscopy system has only recently been introduced and hence there are very few
      studies reporting its use.

      A prospective study from Japan used endocytoscopy on 113 patients to obtain real time
      histological images in vivo during colonoscopy (13). With the ECS system, it was possible to
      observe lesions at the cellular level, evaluate cellular atypia and distinguish between
      neoplastic and nonneoplastic lesions when compared to histology which was used as the gold
      standard. The correlation between the endocytoscopic and histological diagnosis was
      statistically significant. Eleber et al (14) also reported a sensitivity and specificity of
      79% and 90 %, respectively of the ECS system in diagnosing neoplastic lesions in 28 patients
      with colonic lesions. Furthermore the study by Cipoletta et al (15) demonstrated that the
      ECS system provides real time imaging in vivo with clear visualization of cellular details
      and features of dysplasia of aberrant crypt foci, considered to be the earliest precursor of
      colorectal cancer. In addition Rotondano et al (15) also confirmed high positive predictive
      values for diagnosing hyperplastic polyps as well as dysplastic polyps including low, high
      grade dysplasia as well as invasive cancer.

      A recent systematic review of all published studies also confirmed that endocytoscopy is a
      safe and effective new endoscopic imaging technique to obtain in vivo histology and guided
      biopsies with high diagnostic accuracy (17).

      No associated risks related to the endocystoscopy procedures have been reported in all
      published studies (12-17).

      This specific diagnostic tool of in vivo histology with the use of high resolution
      endocytoscopy system would allow endoscopists to perform targeted biopsies and in some cases
      (if warranted based on the in vivo images) to proceed directly to endoscopic resection of
      lesions. It may also guide assessment of the completeness of the endoscopic intervention
      with detection of any residual neoplastic tissue at the index exam as well as on follow up
      colonoscopy exams. Other potential benefits include elimination of random biopsies for
      surveillance of mucosal disease, elimination of sampling error, limitation of unnecessary
      polypectomies, hence ultimately resulting in cost effectiveness and improved patient
      outcomes.

      In summary, endocytoscopy has the potential to fundamentally change the way endoscopy and
      pathology interact by allowing near histological quality imaging in vivo, without the need,
      risk, and cost of tissue removal.

      References:

        1. Hawk E.T, Levin B. Colorectal cancer prevention. J Clin Oncol 2005; 23:378-391.

        2. Hurlstone DP, Fujii T, Lobo AJ. Early detection of colorectal cancer using
           high-magnification chromoscopic colonoscopy. Br J Surg 2002; 89:272-82.

        3. Hurlstone DP, Cross SS, Slater R et al. Detecting diminutive colorectal lesions at
           colonoscopy: a randomized controlled trial of pan-colonic versus targeted chromoscopy.
           Gut 2004; 53:376-380.

        4. Kiesslich R, Fritsch J, Holtmann et al. Methylene blue-aide chromoendoscopy for the
           detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.
           Gastroenterology 2003; 124:880-888.

        5. Kiesslich R, Burg J, Vieth M, et al. Confocal laser endoscopy for diagnosing
           intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004;
           127(3):706-13.

        6. Sakashita M, Inoue H, Kashida H et al. Virtual Histology of Colorectal lesions using
           laser -scanning confocal microscopy. Endoscopy 2003; 35(12):1033-1038.

        7. Polglase AL, McLaren WJ, Skinner SA, Kiesslich R, Neurath MF, Delaney PM. A
           fluorescence confocal endomicroscope for in vivo microscopy of the upper- and the
           lower-GI tract. Gastrointestinal Endosc 2005; 62(5):686-95.

        8. Kiesslich R, Goetz M, Lammersdorf K et al. Chromoscopy-guided Endomicroscopy increases
           the diagnostic yield of Intraepithelial Neoplasia in ulcerative Colitis.
           Gastroenetrology 2007; 132:874-882.

        9. Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett's esophagus and
           associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 2006;
           4(8):979-87.

       10. Kiesslich R, Hoffman A, Goetz M, et al. In vivo diagnosis of collagenous colitis by
           confocal endomicroscopy. Gut 2006; 55(4):591-2.

       11. Kiesslich R, Goetz M, Burg J, et al. Diagnosing Helicobacter pylori in vivo by confocal
           laser endoscopy. Gastroenterology 2005; 128(7):2119-23.

       12. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-Guided Endomicroscopy Increases
           the Diagnostic Yield of Intraepithelial Neoplasia in Ulcerative Colitis.
           Gastroenterology 2007; 132(3):874-82.

       13. Sasajima K, Kudo S, Inoue H et al. Real time in vivo virtual histology of colorectal
           lesions when using the endocytoscopy system. Gastrointestinal endoscopy 2006; 63:
           1010-7.

       14. Eberl T, Jechart G, Probst A et al. Can an endocytoscope system (ECS) predict histology
           when using the endocystoscopy system? Gastrointestinal Endosco 2006; 63:1010-1017.

       15. Cipoletta L, Bianco MA, Rotondano G et al. Endocytoscopy can identify dysplasia in
           aberrant crypt foci of the colorectum: a prospective in vivo study. Endoscopy 2009;
           41:129-132.

       16. Rotondano G, Bianco MA, Salerno R et al. Endocytoscopic classification of preneoplastic
           lesions in the colorectum. Int J Colorectal Disease 25:1111-1116.

       17. Neumann H, Fuchs FS, Vieth M et al. Review article: in vivo imaging by endocytoscopy.
           AP&amp;T 2011;33:1183-1193.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unblinded Analysis of Endocytoscopic Images of Colorectal Lesions (Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology)</measure>
    <time_frame>30 Days (from Colonoscopy)</time_frame>
    <description>Endocytoscopic images of colorectal lesions will be reviewed in an unblinded fashion, in a group of 10 side by side images, by the endoscopists (AMB, NA) and the pathologist (AS). Technical quality of the images will be compared to histology and rated on a scale of 1-5 (1-worst, 3- acceptable, 5-being equal to histology). Only images with a score of 3 or better will be used for analysis. The percentage of cases with at least one adequate image per site will be described. The basic characteristics of images allowing distinction between neoplastic, non-neoplastic and normal tissue will be established.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Endocytoscopy During Colonoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endocystoscopy During Colonoscopy</intervention_name>
    <description>Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.</description>
    <arm_group_label>Endocytoscopy During Colonoscopy</arm_group_label>
    <other_name>endocytoscope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endocytoscope</intervention_name>
    <description>The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.</description>
    <arm_group_label>Endocytoscopy During Colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Age above 18, any patient undergoing screening or surveillance colonoscopy.

        Exclusion Criteria:

          -  Pregnancy

          -  Unwillingness to consent

          -  Lack of any pathological state that would require biopsy at the time of endoscopy
             (will be considered &quot;screen failure&quot; since this will not be known until after consent
             is obtained and sedated endoscopy performed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>December 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
